Keeping heart and kidney medications while controlling potassium
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a medication (SZC) that helps lower high potassium levels, so you can keep taking important heart and kidney drugs (RAASi/MRA). It is for people with heart failure and chronic kidney disease who have high potassium.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your potassium level must be between 5.5 and 6.5 mEq/L at first visit, and between 5.0 and 6.5 mEq/L at a later visit.
- You have heart failure and are on stable doses of RAASi and/or MRA medications for at least 4 weeks.
- You have chronic kidney disease stages 2–5, not on dialysis, with a certain level of kidney function.
- You are 18 years or older.
- You cannot have had a recent heart attack, stroke, or heart surgery within the past 12 weeks.
- You cannot be pregnant, breastfeeding, or planning pregnancy; women of childbearing age must use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the best way to manage heart failure in older adults who also have kidney problems and high potassium levels. It compares different treatment strategies to see which one is safest and most effective.
This study tests if careful potassium management can help people with chronic kidney disease (CKD) safely take higher doses of blood pressure medicines called ACE inhibitors or ARBs, which are known to protect the kidneys. You may be eligible if you have moderate to advanced CKD and are already on a moderate dose of one of these medications.
This trial tests whether closely managing potassium levels during hemodialysis can help protect the heart in patients with kidney failure who are on maintenance dialysis. It aims to reduce the risk of heart problems related to potassium swings.
This trial tests whether a medication called sodium zirconium cyclosilicate can help older adults with heart failure safely take a higher dose of a mineralocorticoid receptor antagonist (MRA), a drug that can improve heart function but may raise potassium levels. The study aims to prevent dangerous high potassium levels while allowing the heart medication to work better.
This trial tests how safe and effective SZC is for children with high potassium levels (hyperkalaemia) over the short term, and possibly long term. It aims to help lower potassium safely and see whether it works well in different pediatric age groups.
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
Hear when a new Chronic Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.